126 related articles for article (PubMed ID: 35419489)
1. Inference of Onset Age of Preclinical State and Sojourn Time for Breast Cancer.
Wu D; Kim S
Med Res Arch; 2022 Feb; 10(2):. PubMed ID: 35419489
[TBL] [Abstract][Full Text] [Related]
2. Estimation of Preclinical State Onset Age and Sojourn Time for Heavy Smokers in Lung Cancer.
Wu D; Rai SN; Seow A
Stat Interface; 2022; 15(3):349-358. PubMed ID: 35936652
[TBL] [Abstract][Full Text] [Related]
3. Inference of Sojourn Time and Transition Density using the NLST X-ray Screening Data in Lung Cancer.
Rahman F; Wu D
Med Res Arch; 2021 May; 9(5):. PubMed ID: 34765725
[TBL] [Abstract][Full Text] [Related]
4. Estimation of sensitivity depending on sojourn time and time spent in preclinical state.
Kim S; Wu D
Stat Methods Med Res; 2016 Apr; 25(2):728-40. PubMed ID: 23129110
[TBL] [Abstract][Full Text] [Related]
5. Estimating age group-dependent sensitivity and mean sojourn time in colorectal cancer screening.
Sung NY; Jun JK; Kim YN; Jung I; Park S; Kim GR; Nam CM
J Med Screen; 2019 Mar; 26(1):19-25. PubMed ID: 30261804
[TBL] [Abstract][Full Text] [Related]
6. Sojourn time and lead time projection in lung cancer screening.
Wu D; Erwin D; Rosner GL
Lung Cancer; 2011 Jun; 72(3):322-6. PubMed ID: 21075475
[TBL] [Abstract][Full Text] [Related]
7. Estimation of mean sojourn time in breast cancer screening using a Markov chain model of both entry to and exit from the preclinical detectable phase.
Duffy SW; Chen HH; Tabar L; Day NE
Stat Med; 1995 Jul; 14(14):1531-43. PubMed ID: 7481190
[TBL] [Abstract][Full Text] [Related]
8. A Bayesian nonlinear mixed-effects disease progression model.
Kim S; Jang H; Wu D; Abrams J
J Biom Biostat; 2015 Dec; 6(5):. PubMed ID: 26798562
[TBL] [Abstract][Full Text] [Related]
9. Robust modeling in screening studies: estimation of sensitivity and preclinical sojourn time distribution.
Shen Y; Zelen M
Biostatistics; 2005 Oct; 6(4):604-14. PubMed ID: 15860542
[TBL] [Abstract][Full Text] [Related]
10. Estimating key parameters in periodic breast cancer screening-application to the Canadian National Breast Screening Study data.
Chen Y; Brock G; Wu D
Cancer Epidemiol; 2010 Aug; 34(4):429-33. PubMed ID: 20434974
[TBL] [Abstract][Full Text] [Related]
11. Estimation of sojourn time in chronic disease screening without data on interval cases.
Chen TH; Kuo HS; Yen MF; Lai MS; Tabar L; Duffy SW
Biometrics; 2000 Mar; 56(1):167-72. PubMed ID: 10783792
[TBL] [Abstract][Full Text] [Related]
12. Estimating key parameters in FOBT screening for colorectal cancer.
Wu D; Erwin D; Rosner GL
Cancer Causes Control; 2009 Feb; 20(1):41-6. PubMed ID: 18704710
[TBL] [Abstract][Full Text] [Related]
13. Estimating the natural progression of non-invasive ductal carcinoma in situ breast cancer lesions using screening data.
Weedon-Fekjær H; Li X; Lee S
J Med Screen; 2021 Sep; 28(3):302-310. PubMed ID: 32854582
[TBL] [Abstract][Full Text] [Related]
14. Bayesian evaluation of breast cancer screening using data from two studies.
Myles JP; Nixon RM; Duffy SW; Tabar L; Boggis C; Evans G; Shenton A; Howell A
Stat Med; 2003 May; 22(10):1661-74. PubMed ID: 12720303
[TBL] [Abstract][Full Text] [Related]
15. Test sensitivity in a prospective cancer screening program: A critique of a common proxy measure.
Lange J; Zhao Y; Gogebakan KC; Olivas-Martinez A; Ryser MD; Gard CC; Etzioni R
Stat Methods Med Res; 2023 Jun; 32(6):1053-1063. PubMed ID: 37287266
[TBL] [Abstract][Full Text] [Related]
16. Quantifying the duration of the preclinical detectable phase in cancer screening: a systematic review.
Geurts SME; Aarts AMWM; Verbeek ALM; Chen THH; Broeders MJM; Duffy SW
Epidemiol Health; 2022; 44():e2022008. PubMed ID: 34990529
[TBL] [Abstract][Full Text] [Related]
17. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations.
Shen Y; Zelen M
J Clin Oncol; 2001 Aug; 19(15):3490-9. PubMed ID: 11481355
[TBL] [Abstract][Full Text] [Related]
18. A multistate survival model of the natural history of cancer using data from screened and unscreened population.
Bhatt R; van den Hout A; Pashayan N
Stat Med; 2021 Jul; 40(16):3791-3807. PubMed ID: 33951215
[TBL] [Abstract][Full Text] [Related]
19. Age specific sensitivity and sojourn time in a breast cancer screening programme (DOM) in The Netherlands: a comparison of different methods.
Brekelmans CT; Westers P; Faber JA; Peeters PH; Collette HJ
J Epidemiol Community Health; 1996 Feb; 50(1):68-71. PubMed ID: 8762357
[TBL] [Abstract][Full Text] [Related]
20. Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches.
Prevost TC; Launoy G; Duffy SW; Chen HH
Am J Epidemiol; 1998 Sep; 148(6):609-19. PubMed ID: 9753016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
